Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study

被引：1
|
作者：
Mohan, K. [1 ]
Prajapati, A. [2 ]
Kothari, R. K. [3 ]
Mondal, S. [4 ]
Nagarkar, R. [5 ]
Kane, S. B. [6 ]
Santa, A. [1 ]
Dadke, D. [7 ]
机构：
[1] Basavatarakam Indo Amer Canc Hosp & Res Inst, Med Oncol, Hyderabad, India
[2] Curateq Biol Private Ltd, Clin Dev, Hyderabad, India
[3] Narayana Multispecialty Hosp, Med Oncol, Ahmadabad, Gujarat, India
[4] Nilratan Sircar Med Coll & Hosp, Radiotherapy, Kolkata, India
[5] HCG Manavata Canc Ctr, Surg Oncol, Nasik, India
[6] RST Reg Canc Ctr, Med Oncol, Nagpur, Maharashtra, India
[7] Curateq Biol Private Ltd, Hyderabad, India
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.201
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
67P
引用
收藏
页码：S1491 / S1491
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients
    Zhu, Zhen-Li
    Zhang, Jun
    Chen, Mei-Lan
    Li, Ke
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (12) : 7111 - 7116
  • [22] Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial
    Xu, Binghe
    Zhang, Qingyuan
    Sun, Tao
    Li, Wei
    Teng, Yue'e
    Hu, Xichun
    Bondarenko, Igor
    Adamchuk, Hryhoriy
    Zhang, Liangming
    Trukhin, Dmytro
    Wang, Shusen
    Zheng, Hong
    Tong, Zhongsheng
    Shparyk, Yaroslav
    Yang, Futang
    Yu, Haoyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    BREAST, 2025, 80
  • [23] Trial comparing the safety, efficacy and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+early breast cancer
    Krivorotko, P.
    Manikhas, A.
    Moiseenko, F.
    Poddubskaya, E.
    Neciosup, S. P.
    Gopichand, M.
    Osynskyi, D.
    Haynes, T.
    Lai, J.
    Mills, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S419 - S419
  • [24] Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data
    Li, Rubi K.
    Lipatov, Oleg
    Adamchuk, Hryhoriy
    Vladimirov, Vladimir
    Yanez, Eduardo
    Banchero, Patricia
    Freyman, Amy
    Hilton, Fiona
    Thiele, Alexandra
    Vana, Alicia
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC)
    Stebbing, Justin
    Valerievich, Yauheni
    Baryash, Baranau Valery
    Manikhas, Alexey
    Moiseyenko, Vladimir
    Dzagnidze, Giorgi
    Javrid, Edvard
    Boliukh, Dmytro
    Stroyakovskiy, Daniil
    Pikiel, Joanna
    Eniu, Alexandru E.
    Komov, Dmitry
    Zautashvili, Zakaria
    Morar-Bolba, Gabriela
    Li, Rubi Khaw
    Lifirenko, Igor
    Rusyn, Andriy V.
    Lee, Sang Joon
    Lee, Sung Young
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Trastuzumab Biosimilar for HER2-positive Breast Cancer and Stomach Cancer Effective and economical Treatment with a new Trastuzumab Biosimilar
    不详
    BREAST CARE, 2019, 14 (05) : 338 - 339
  • [27] Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
    Esteva, F. J.
    Baranau, Y.
    Baryash, V.
    Manikhas, A.
    Moiseyenko, V.
    Dzagnidze, G.
    Zhavrid, E.
    Boliukh, D.
    Stroyakovskiy, D.
    Pikiel, J.
    Eniu, A.
    Komov, D.
    Zautashvili, Z.
    Morar-Bolba, G.
    Li, R. K.
    Lifirenko, I.
    Rusyn, A.
    Lee, S. J.
    Yu, S.
    Stebbing, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] A prospective real-world national study to evaluate the efficacy and safety of adjuvant biosimilar trastuzumab in the treatment of HER2-positive breast cancer
    Alves, Leandro
    Gagliato, Debora
    de Paula, Mayara
    Cardoso, Ana Carolina
    Alcantara, Alexandre
    Precivale, Maristela
    Castilho, Vivienne
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
    Chia, Stephen
    Clemons, Mark
    Martin, Lee-Ann
    Rodgers, Angela
    Gelmon, Karen
    Pond, Gregory R.
    Panasci, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2773 - 2778
  • [30] Efficacy of neratinib neoadjuvant therapy in a pre-clinical model of HER2+ve breast cancer brain metastasis
    Nagpal, Aadya
    Redvers, Rick P.
    Ayton, Scott
    Anderson, Robin
    Loi, Sherene
    Pouliot, Normand
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 61 - 61
12345